Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,625 JPY | -3.99% | -1.31% | -3.62% |
Sales 2024 * | 1,569B 10.36B | Sales 2025 * | 1,674B 11.05B | Capitalization | 2,914B 19.24B |
---|---|---|---|---|---|
Net income 2024 * | 81.96B 541M | Net income 2025 * | 153B 1.01B | EV / Sales 2024 * | 2.18 x |
Net Debt 2024 * | 503B 3.32B | Net Debt 2025 * | 440B 2.91B | EV / Sales 2025 * | 2 x |
P/E ratio 2024 * |
33.8
x | P/E ratio 2025 * |
18.5
x | Employees | 14,484 |
Yield 2024 * |
4.31% | Yield 2025 * |
4.58% | Free-Float | 98.82% |
Latest transcript on Astellas Pharma Inc.
1 day | -3.99% | ||
1 week | -1.31% | ||
Current month | -1.60% | ||
1 month | -2.02% | ||
3 months | -3.13% | ||
6 months | -24.98% | ||
Current year | -3.62% |
Managers | Title | Age | Since |
---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 61 | 86-03-31 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 52 | Oct. 31 |
Kenji Yasukawa
CHM | Chairman | 63 | 86-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Takashi Tanaka
BRD | Director/Board Member | 67 | 21-05-31 |
Mamoru Sekiyama
BRD | Director/Board Member | 74 | 17-05-31 |
Naoki Okamura
CEO | Chief Executive Officer | 61 | 86-03-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
11.47% | 14 M€ | +10.37% | ||
2.09% | 245 M€ | +19.57% | ||
2.01% | 45 M€ | +22.83% | ||
1.99% | 11 M€ | +15.53% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 1,625 | -3.99% | 9,670,000 |
24-03-27 | 1,692 | +1.07% | 12,397,500 |
24-03-26 | 1,674 | +1.27% | 8,019,600 |
24-03-25 | 1,654 | -1.11% | 7,191,500 |
24-03-22 | 1,672 | -0.30% | 10,452,200 |
Delayed Quote Japan Exchange, March 28, 2024 at 02:00 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.62% | 20.05B | |
+33.46% | 701B | |
+26.24% | 571B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 319B | |
+0.74% | 210B | |
+2.95% | 210B | |
-6.05% | 201B | |
-3.61% | 157B |